Regenerating Knee Cartilage with Stem Cells: Groundbreaking Clinical Trial Underway at Andrews Institute

GULF BREEZE, Fla.July 6, 2017 /PRNewswire/ — A groundbreaking randomized clinical trial (RCT) evaluating the use of a patient’s own stem cells to regenerate knee cartilage is underway at Andrews Institute for Orthopaedics & Sports Medicine in Gulf Breeze, Florida. The study, led by Adam Anz, M.D., an orthopaedic surgeon at Andrews Institute, is the first multicenter Phase II United States Food and Drug Administration (FDA) observed RCT of its kind.

While early regenerative medicine treatment options utilizing stem cells are currently being used and studied at Andrews Institute to facilitate healing of ligaments and tendons, this is the first time stem cells will be evaluated in a clinical trial to regenerate cartilage in massive knee cartilage injuries.

“In the United States, there are currently no proven treatment options that utilize stem cells to regenerate a patient’s knee cartilage once it has deteriorated,” said Dr. Anz. “This clinical trial is a monumental step to get FDA approved stem cell technology to our patients.”

The study is being conducted in conjunction with the Kuala Lumpur Sports Medicine Center (KLSMC) in Kuala Lumpur, Malaysia, and will be funded in part by the Malaysian government. It will attempt to replicate outcomes from clinical treatments currently available to patients in Malaysia using a cartilage regeneration technology developed by Dr. Khay-Yong Saw, an orthopaedic surgeon who practices at KLSMC.

“The whole concept of regenerating cartilage is totally different from what’s being used now to treat damaged cartilage,” said Dr. Saw. “We are hoping this study will help the FDA evaluate the safety and the effectiveness of this clinical application.”

The RCT will be facilitated through the Andrews Research & Education Foundation, an independent 501(c)(3) not-for-profit entity that serves as the research and education wing of Andrews Institute. The study could take up to six years; however, there may be a possibility to stop the RCT earlier if results show statistical significance.

Baptist Health Care opened the Andrews Institute in 2007. Named for internationally renowned orthopaedic surgeon James R. Andrews, M.D., the Andrews Institute has secured northwest Florida as a cradle for musculoskeletal treatments and research.

SOURCE Andrews Institute for Orthopaedics & Sports Medicine

Related Links

http://www.theandrewsinstitute.com

OrthoSpace Announces the Publication of Positive InSpace™ Study

OrthoSpace Ltd. (“OrthoSpace” or “the Company”) today announced the publication of positive data on the use of the InSpace™ subacromial spacer for the treatment of massive rotator cuff tears. The case series of 39 shoulders (37 patients) was published in Arthroscopy and demonstrated improved function and reduced pain in patients treated with the InSpace System.

“Patients who fail conservative therapy for massive rotator cuff repair have historically had few options for further treatment of this debilitating, painful condition,” said Julien Deranlot, M.D., principal investigator of the study and an orthopedic surgeon at Clinique Drouot in Paris, France. “The InSpace provides a safe and reliable surgical alternative that can improve shoulder pain and function, allowing patients to have a better quality of life post-operatively.”

The InSpace System consists of a biodegradable balloon spacer deployed in the subacromial space between the acromion and the humeral head, allowing smooth gliding and frictionless movement between the two bones and emulating the function of the original bursa. It is usually placed arthroscopically in a procedure that requires only 10 minutes to perform.

This study assessed clinical, functional and radiographic outcomes for all patients with symptomatic massive irreparable rotator cuff tears who were treated with the InSpace at the Clinique Drouot between January 2011 and December 2014. Patients included in this study had a minimum of one year and up to three years of follow-up at the time of analysis.

The investigators reported the following results:

  • Range of motion was significantly increased for all patients in anterior elevation, abduction and external rotation.
  • The mean Constant score, which measures pain, activity level and function, improved from 40 (±14.6) (45 [±15.2] when adjusted for age and gender) at baseline to 59 (±13.7) at one year, and up to 64 (±13.6) (adjusted = 76 [±17.1]) (P < 0.0001) at last follow-up. Notably, there was a significant improvement between the one-year follow-up and three-year follow-up regarding the adjusted Constant score (P=0.02).
  • At last follow-up, adjusted Constant score was excellent (greater than 100 points) for three shoulders (9%), good (86-99 points) for eight (23%), fair (65-85 points) for sixteen (45%), and poor (fewer than 65 points) for eight shoulders (23%).
  • Among the radiographic outcomes, when assessing for Hamada score (a measure of osteoarthritis), four shoulders progressed by one radiographic stage (15%), and two shoulders progressed by three stages (4%). 32 shoulders had no progression during follow-up.

“We continue to be encouraged by the compelling clinical improvements we see in patients treated with the InSpace System, which are in line with the strong results demonstrated in previous studies,” OrthoSpace CEO Itay Barnea commented. “The system offers a safe, minimally invasive option that can be effectively used to relieve pain and improve shoulder function for patients, especially in elderly patients with chronic pain and disability, poor tissue quality or other health issues, who may not have alternative treatment options.”

The InSpace System is CE Marked in Europe and Israel and is investigational in the U.S. and Canada, where it is currently being evaluated in a prospective, single-blinded, multi-center, randomized, controlled study that will enroll up to 184 patients.

About OrthoSpace Ltd.
OrthoSpace is a privately held medical device company located in Caesarea, Israel. The Company’s product, InSpace, is an orthopedic biodegradable balloon system that is simple, safe and a minimally invasive method that addresses unmet clinical needs in rotator cuff repair. InSpace is CE Marked and commercialized in Europe and Israel and has been granted an Investigational Device Exemption (IDE) to initiate a pivotal human clinical study of the InSpace System in the United States.

Oska Wellness is Nominated in the 2017 Startup of the Year Competition – West [Pacific – Southern California]

Who should be named Startup of the Year from the West [Pacific – Southern California] region? You can share your opinion by voting for your favorite startup in our Reader’s Choice Poll below. Reader’s Choice Poll voting will help guide the selection of the top 100 startup semifinalists who will compete for cash, prizes and more, at the Innovate! and Celebrate conference in San Francisco on October 9th – 11th, 2017. The deadline to vote is July 12th.

There’s a “Click to Vote” link next to each startup below, vote for the startup you like the best located in the West [Pacific – Southern California] region:

Airspace Technologies (Carlsbad, CA) [Click to Vote]
Airspace Technologies offers end-to-end logistics solutions: we take a modern approach to time critical shipments by enabling technology.

Bezelhub (Santa Monica, CA) [Click to Vote]
Bezelhub is jewelry in your pocket. Just tap a button and a luxury watch is delivered right to you, giving you the access you need, anywhere.

Blue (Riverside, CA) [Click to Vote]
Blue is a mobile application that introduces people using bluetooth low energy without the touch of a button.

Bottlerocket (Santa Monica, CA) [Click to Vote]
BottleRocket is the first on-demand service that rewards users for recycling.

Decorator (Santa Monica, CA) [Click to Vote]
Decorator is crowdsourcing interior design. Think The Sims for real-life homes where other people redesign your room with new paint & furniture.

LineStar by Fantasy Sports Co. (San Diego, CA) [Click to Vote]
Fantasy Just Got Fun Again as LineStar is the #1 Companion for DraftKings, FanDuel, and Yahoo Daily Fantasy!

GoShare (San Diego, CA) [Click to Vote]
GoShare connects truck and van owners with people and business who need help moving, hauling and delivering large items on demand.

Lemonlight (Marina del Rey, CA) [Click to Vote]
Lemonlight creates high-quality affordable video content at scale. In 3 years, the company has produced 4000+ videos for brands nationwide.

LuxeRoom4Day (Beverly Hills, CA) [Click to Vote]
LuxeRoom4Day is a simple, fast, and secure way to book a 5-star luxury hotel day rooms, with prices up to 70 percent cheaper than the night rates.

Markett (Venice, CA) [Click to Vote]
Markett is a performance based platform that systematizes word of mouth marketing by providing ambassadors with all the tools they need to acquire new customers for their favorite brands.

Nutra.io (Playa Vista, CA) [Click to Vote]
Nutra.io is an end-to-end solution to decoding your genetic data into actions to help you eat right and supplement your body based on your genome and track your results.

Oska Wellness (Carlsbad, CA) [Click to Vote]
Oska Wellness is a new health-tech, wearable pain relief device that can help areas of the body prone to injury and degeneration.

Raken (Carlsbad, CA) [Click to Vote]
Raken’s software is a shot of adrenaline for a construction industry still stuck in the paper and pencil era.

Renly (Manhattan Beach, CA) [Click to Vote]
A marketplace for renters and sub-renters.

RepWatch (Westlake Village, CA) [Click to Vote]
RepWatch promotes efficient recovery for physical therapy patients by providing a system that encourages and motivates patients to stay on track.

SPARE. (Santa Monica, CA) [Click to Vote]
SPARE. is a community-based cash network allowing cash-back without a purchase. We empower merchants to dispense cash directly from their cash registers and consumers order cash directly from their mobile devices.

SwiftChange (San Diego, CA) [Click to Vote]
SwiftChange lets you receive change on your phone after a cash payment so you can capture the value of change without the hassle of coins!

Tampon Tribe (Santa Monica, CA) [Click to Vote]
Tampon Tribe is a movement that offers affordable access to organic feminine hygiene via online subscription for $8 a month and deliver to your home.

Trulo (Manhattan Beach, CA) [Click to Vote]
Trulo is the home for your best kept secrets of your locals-only spots in your city that you share with your hand-selected travel tribe.

Youngry (Newport Beach, CA) [Click to Vote]
Youngry provides early stage entrepreneurs “Young In Spirit, Hungry In Ambition” the best mentor driven content on the planet.

Thank you to our Startup of the Year sponsors and partners

OrthoIndy Performs First Meniscus Replacements in Indiana with NUsurface® Implant

June 27, 2017

INDIANAPOLIS–(BUSINESS WIRE)–OrthoIndy and Active Implants, a company that develops orthopedic implant solutions, today announced that the first meniscus replacement procedures have been performed in Indiana. Dr. Jack Farr, orthopedic surgeon at OrthoIndy, was the first to perform the procedure on Greenwood resident Jason Scott. OrthoIndy is the only center in the state – and just one of 10 sites nationwide – participating in the VENUS (Verification of the Effectiveness of the NUsurface® System) clinical trial, which is enrolling patients with persistent knee pain after loss of meniscus cartilage to assess the safety and effectiveness of the investigational NUsurface Meniscus Implant compared to non-surgical standard of care.

The meniscus is a tissue pad between the thigh and shin bones. Once it is damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies (to remove the torn portion of the meniscus) are performed in the U.S. every year, more than the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus partial excision surgery.

Scott suffered a knee injury resulting in a meniscus tear while playing high school basketball 18 years ago. This injury led the 36-year-old to undergo two partial meniscectomy surgeries on his left knee, which allowed him initially to get back to playing basketball and softball. However, the knee pain flared up over the past few years to where Scott began to experience consistent knee pain during any activity, including participating in sports, playing with his kids and simply sitting in the car for too long.

“We don’t have many surgical options for patients like Jason,” Dr. Farr said. “He is too young for knee replacement surgery and was not interested in the time it takes to recover from tibial realignment or meniscal transplant surgery. We hope NUsurface not only alleviates his pain and gets him back to his normal activities, but possibly helps him delay or avoid knee replacement surgery.”

Dr. Farr implanted the device in May 2016 through a small incision in Scott’s knee. Following a full six-week physical therapy regimen,Scott was able to gain full range of motion as well as resume daily activities. It has been one year since he received the implant and Scott’s knee continues to be stable. He has been able to play basketball again, go to concerts and sporting events, and take family vacations without worrying about knee pain.

“I feel fortunate that at the young age of 36, I’m able to receive a meniscus implant instead of living with persistent pain that could lead to an unwanted knee replacement later in life,” Scott said. “As a father of two young girls, I need to be as mobile and active as my kids are – the NUsurface implant has helped to alleviate my knee pain so I can play sports with my kids, travel with my family and get back to my athletic lifestyle.”

The NUsurface Meniscus Implant is inserted into the knee joint through a small incision and patients typically can go home on the same day of the operation. After surgery, they undergo a six-week rehabilitation program. NUsurface has been used in Europe since 2008 and Israel since 2011.

About the Clinical Trial

As part of the process to gain regulatory approval in the U.S., the VENUS (Verification of the Effectiveness of the NUsurface® System) study will enroll approximately 130 patients at orthopedic centers in the U.S., Europe and Israel. Sites in the U.S. include Indiana (Indianapolis), Massachusetts (Boston), New York (Albany, Rochester and New York), North Carolina (Durham), Ohio (Columbus), Tennessee (Memphis) and Virginia (Richmond). Participants who meet study requirements and agree to enter the trial are randomized to receive either the NUsurface device or non-surgical treatment, which is the current standard of care for patients with persistent knee pain following meniscus surgery. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the VENUS study, please call (844) 680-8951 or visit www.meniscus-trial.com.

About the NUsurface® Meniscus Implant

In the U.S., the NUsurface® Meniscus Implant, from Active Implants LLC, is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. The NUsurface Meniscus Implant is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissue. The NUsurface device mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. It is inserted into the knee joint through a small incision, and patients typically can go home soon after the operation. After surgery, patients undergo a six-week rehabilitation program. The NUsurface device has been used clinically in Europe since 2008 and Israel since 2011.

About OrthoIndy and the OrthoIndy Hospital

Founded over 50 years ago, OrthoIndy is one of the most highly respected orthopedic practices in the Midwest. With over 70 physicians providing care to central Indiana residents from more than 10 convenient locations, OrthoIndy provides leading-edge bone, joint, spine and muscle care. OrthoIndy physicians also provide care to the Indiana Pacers, Indiana Fever, Indianapolis Indians and Dance Kaleidoscope, as well as local colleges and high schools.

Owned and operated by OrthoIndy physicians, OrthoIndy Hospital is central Indiana’s first specialty hospital with a direct focus on bone, joint, spine and muscle care and the most technologically advanced facility available for orthopedics in the Midwest. As a physician-owned hospital model, OrthoIndy Hospital’s top priorities are patient safety, satisfaction and outcomes.

Quality patient care serves as the foundation for the physician-owned and operated hospital, which is evident in the ratings received from Press Ganey Associates, Inc. From 2013 to 2016 OrthoIndy Hospital was named a Guardian of Excellence Award winner for consistently achieving the 95th percentile of performance in patient satisfaction. From 2009 to 2012, OrthoIndy Hospital was named the Summit Award Winner for sustaining the highest level of customer satisfaction for three or more consecutive years.

For more information on OrthoIndy, please call (317) 802-2000 or visit http://orthoindy.com/.

About Active Implants

Active Implants, LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in The Netherlands, with R&D facilities in Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

New Oska® Pulse Shows to Reduce Pain in Pilot Clinical Study

CARLSBAD, CA – June 13, 2017 – Oska Wellness, a technology company committed to developing consumer health and wellness products, has released a third-party, independent study showing significant results that Oska Pulse can reduce pain and improve mobility in a phase I clinical trial. Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

The study was authored by Dr. Kathy Davis, Associate Professor of Nrsing at Gordon State College, Ga. and published by Dr. Mark D. Wiederhold, Chief Executive Officer at the Virtual Reality Medical Center at Scripps Memorial Hospital in La Jolla, Ca.

The findings were published in Journal of Pain Management (volume 10, issue 2) and suggest that Oska Pulse is a very effective method in managing pain relief. Journal of Pain Management is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of pain management.

Of the preliminary results, the most promising findings include:

  • 80% of participants experienced an improvement in pain reduction
  • 40% reported a perceived improvement in overall mobility
  • 30% of the total participants remained pain-free or nearly pain-free for the duration of the four week trial

“I think this is a good initial report with solid results – especially with helping mobility,” said Dr. Davis. “With chronic pain as a common problem seen in clinical practice, patients and providers are seeking alternatives to pain management that are safe and effective.  It is critical to continue to study the device with larger samples of the population to further evaluate the full potential of Oska Pulse.”

“We are excited for the people living with chronic and acute pain to have access to new data supporting the use of non-drug, noninvasive pain-relief technology as demonstrated in this study,” said Greg Houlgate, CEO/President Oska Wellness.  “We are committed to helping people return to an active lifestyle without the use of drugs or other invasive techniques.”

Oska Pulse, with proprietary eTec™ Pulse Technology, is a small, portable, hands-free wearable device that safely optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, a longtime therapy used by medical practitioners to help people live a more active, pain-free and drug-free lifestyle.

Additional research has shown that PEMF signals pass through bone and other tissue to aid the body in delivering more nutrients and oxygen to tissues while removing waste products. The Oska Pulse’s “Sequential Protocol Programming” delivers four frequencies specifically related to muscle relaxation, bone tissue circulation, capillary dilation and pain reduction.

By helping to release the body’s natural endorphins, the Oska Pulse helps reduce pain and promotes increased range of motion. By dilating blood vessels, it reduces inflammation and the increased oxygen rich blood flow speeds muscle recovery.

About Oska Wellness 
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition.

 

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

 

The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

 

 

 

 

The Case Against – and for – Arthroscopic Knee Surgery

By Michael O. Schroeder, Staff Writer | June 22, 2017

The prospect of resolving nagging knee pain – or discomfort that’s come on fairly sudden – drives many patients to go under the knife, specifically to have an arthroscopic knee procedure done.

During the procedure, an orthopedic surgeon inserts a tiny camera – or arthroscope – through a small incision to view the inside of the knee. The doctor then attempts to surgically address the knee pain, such as making repairs to a torn meniscus – a C-shaped disc that cushions the knee – or realigning a misaligned patella or kneecap.

“There are some limited circumstances where it’s helpful,” says Dr. Reed Siemieniuk, an internist in Toronto and a doctorate student in health research methodology at McMaster University in Hamilton, Ontario. That includes young patients who have sports injuries, or tears in the ligaments of the knee, he says, and patients who have bleeding in the knee – to try to figure out where the bleeding is coming from and address that. The surgery could also benefit individuals of any age who’ve suffered a traumatic injury to the knee, such as a meniscus tear. An example of a good candidate for arthroscopic knee surgery would bea 30-year-old who twists his knee getting up from a seated position or while playing tennis, says Dr. Joseph Bosco, a professor and vice chair of the department of orthopedic surgery at NYU Langone Medical Center.

But a meta-analysis led by Siemieniuk of research on arthroscopic knee surgery strongly recommended against knee scoping “in nearly all patients with degenerative knee disease.” The clinical practice guideline was published in the BMJ in May. The analysis evaluated arthroscopic knee surgery for degenerative knee disease, which is often synonymous with knee arthritis. “It is knee pain or locking that occurs with use or overuse. The most common risk factor is being overweight or obese,” Siemieniuk explains. “We use the term degenerative knee disease rather than arthritis because some surgeons restrict the diagnosis of arthritis to those diagnosed by X-ray or MRI when in reality, many people have degenerative knee disease with normal X-rays and MRIs.” Meniscus tears are also a common finding in those with arthritis, or degenerative knee disease, and are not associated with knee symptoms, but are often used as a reason to operate, he adds.

‘Cool’ New Knee Procedure Eases Arthritis Pain Without Surgery

by and

A new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.

The treatment, recently approved by the Food and Drug Administration, is called “cooled radio frequency ablation” and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don’t make them a good candidate for surgery.

Marketed as “Coolief”, the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain. Coolief doesn’t repair arthritis in the knee, but eases the pain, helping patients go back to activities without discomfort and fewer medications.

“What we’re changing is the wiring of the knee — so we’re taking away the pain signal and interrupting it,” Dr. Amin Sandeep, a pain specialist at Rush University Medical Center in Chicago who performs the procedure, told NBC News.

One 2016 study compared Coolief to popular cortisone injections, with patients reporting greater, longer-lasting pain relief with the new treatment than injections. Coolief reduces pain for about to 6 to 12 months, depending on how fast the nerves in the knee regenerate.

 

READ THE REST HERE

Oska® Wellness Announced as the Presenting Sponsor for the 4th Annual Midwest Pain Treatment Education Expo

CARLSBAD, Calif., April 18, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing cutting-edge consumer health and wellness products, is the presenting sponsor for the 4th Annual Midwest Pain Treatment Education Expo, August 13, 2017 at the Hilton Hotel, Northbrook, Illinois.

Oska Wellness will have a booth at the Expo with top Oska executives on hand to showcase the benefits of the Oska® Pulse, a revolutionary wearable device to combat pain. The company has donated 10 Oska Pulse devices to be given away as door prizes, along with 20 additional devices to be gifted (to the first 10 people in line at 8 a.m. and again to the first 10 people at 1 p.m.).

The Midwest Pain Treatment Education Expo is produced by Gracie Bagosy-Young, a chronic pain patient advocate and president of the GG Chronic Pain Foundation, whose mission is to raise awareness of chronic pain conditions and educate the chronic pain community on non-drug options and current research.

“This is our biggest outreach event, with outstanding speakers, exhibitors and attendees from all over the country, and will be streamed on Facebook Live and Livestream all over the world,” said Bagosy-Young. “I’m thrilled that Oska Wellness has joined me as presenting sponsor for the Expo and to help spread the message about new non-drug options for managing pain.”

Oska Wellness recently unveiled the new Oska Pulse a small, portable, hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology, a longtime therapy used by medical practitioners to help people enjoy more active, pain-free and drug-free lives.

“We’re very excited to sponsor the Midwest Pain Treatment Education Expo and share our mission on new ways to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness. “Oska Pulse is a smart, safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have chronic pain. We will be showcasing Oska Pulse and the benefits of PEMF technology to hundreds of attendees at the Expo.”

For more information and ticket options for the Midwest Pain Education Expo, please contact Gracie Bagosy-Young at gracie@ggpainadvocacy.com.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with over 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

 

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

 

 

CONTACT:
Robin Carr, Oska, Inc.
415-971-3991
155323@email4pr.com

SOURCE Oska Wellness

Spring Loaded Technology Officially Launches LevitationTM, the World’s First Compact Bionic Knee Brace, with support from Government of Canada

HALIFAX, NS – June 9, 2017 – Spring Loaded Technology announces the official launch of its LevitationTM bionic knee brace for consumer sales across North America, and is now welcoming commercial partnerships with clinics, distributors, and brace retailers across Canada. The product launch takes place as the Government of Canada announces a $2.46-million investment through the Atlantic Canada Opportunities Agency’s Atlantic Innovation Fund (AIF).

Spring Loaded Technology CEO Chris Cowper-Smith describes the announcement as “The next chapter in our journey to change and improve lives in a big way.” COO Dawn Umlah added, “With the support of ACOA, combined with our research and development efforts and leading-edge product development, it’s a game changer. We’re proud to be able to put the world’s first and only compact, bionic knee brace into the hands of consumers on a large scale.”

As the world’s first bionic knee brace, Levitation™ uniquely enhances knee strength, mobility, and endurance by storing energy as the leg bends and then returning that energy as the leg straightens. Current users range from performance athletes, to manual laborers, to people with osteoarthritis. Levitation has proven useful for most knee injuries and conditions.

“The team at Spring Loaded Technology is transforming the versatility of assistive devices,” says

Darren Fisher, Member of Parliament for Dartmouth-Cole Harbour. “They represent a broader

life sciences community working on research that brings solutions to the marketplace. Targeted

investments such as these are helping us grow beyond our borders in line with our Atlantic

Growth Strategy.”

After successfully securing USD $208,000 through an Indiegogo crowdfunding campaign, delivering a $1-million contract for the Canadian forces, and fulfilling hundreds of consumer pre-orders, the Nova Scotia company is entering what they call real-time production. With bolstered manufacturing capacity, product improvements, and increased demand, Spring Loaded Technology is positioned to deliver Levitation across North America, to help people do more of what they love.

To learn more about Levitation™ and Spring Loaded Technology, or to inquire about partnership opportunities, visit www. springloadedtechnology.com.

About Spring Loaded Technology

Spring Loaded Technology is an award-winning company based in Halifax, Nova Scotia, which has designed an entirely new knee bracing technology to enhance the strength and power of the leg muscles. By increasing leg strength, their technology can be used in a wide range of applications including: mobility assistance, fatigue reduction, injury prevention/rehabilitation, and performance enhancement. The company was founded in 2012.

 

Media Contacts:

Kaleigh DeHart

Uproar PR for Spring Loaded Technology

Office: 321.236.0102

Email: kdehart@uproarpr.com

 

Alex Smith

Director of Communications and Outreach, Atlantic Canada Opportunities Agency

Cell: (902) 830-3839
Office: (902) 426-9417
E-mail: alex.smith@canada.ca

 

Juvent Names Scott D. Boden, MD as Chief Medical Advisor

RIVIERA BEACH, FL–(Marketwired – June 07, 2017) – Juvent (www.juvent.com) a leader in orthopaedic regenerative therapies for bone and musculoskeletal health announced today the engagement of Scott D. Boden, MD as Chief Medical Advisor. Dr. Boden is a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopeadics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs.

Dr. Boden has received numerous awards for his work and is the author of more than 175 peer-reviewed articles on spine and basic science topics; as well as 30 chapters and seven textbooks. He is co-editor of Seminars in Spine Surgery, a deputy editor of SPINE, and a reviewer for the Journal of Bone and Joint Surgery, the Journal of Bone and Mineral Research, and the European Spine Journal.

“Dr. Boden brings in-depth experience and perspective to our group and has a unique blend of medicine, science, and business skills,” said Rush Simonson, Chairman & CEO of Regenerative Technologies Corporation. “His reputation and expertise will help us in our quest to expand the clinical value of the Juvent technology.”

In 2013, Dr. Boden served as President of the American Orthopaedic Association. He received his B.A. and M.D. from the University of Pennsylvania and completed an Orthopaedic Residency at The George Washington University Medical Center, followed by a Spine Fellowship at Case Western Reserve University Hospitals.

Additionally, Dr. Boden, Emory Orthopaedics and Spine are also pioneering a sports team and academic health-care partnership with the Atlanta Hawks and P3 (Peak Performance Project) in a soon to open 90,000-square foot, $50 million-dollar facility. Juvent is playing an ever-increasing role in professional sports as their device helps to rehab athletes and speed recovery time after training. Olympic gold medal tennis champion, Mike Bryan, uses Juvent daily as well as many other national football players, such as Eric Wood, Center with the Buffalo Bills.

Juvent’s presence in physical therapy centers continues to grow with one leading therapy franchise putting over 80% of their patients on Juvent at each visit. “Dr. Boden’s experience and expertise in bone health is widely recognized and he will help drive Juvent’s product development and clinical applications,” said Juvent President, Peter Simonson.

“We are just before entering our next round of funding to complete development and production of a low-cost consumer unit to meet the demand of a broader consumer market. Over 50 million people who suffer from osteoarthritis in the U.S. could benefit from this safe, non-invasive technology,” said Chairman & CEO Rush Simonson.

Juvent’s Micro-Impact Platform® is registered as a FDA Class I medical exercise and rehabilitation device. Juvent uses a unique, patented resonant wave technology to deliver thousands of low-magnitude and high-frequency micro-impacts that enter through the heels of the feet and move up the entire body. These micro-impacts safely stimulate the body’s muscles and bones to rebuild. Users stand on the Juvent for as little as 10 minutes per day and many begin to feel joint pain relief within days. Juvent’s platform is recommended and used by world-renowned trainers, doctors, physical therapists, and chiropractors. Juvent holds over 26 patents worldwide on its technology.

Juvent’s platform is also used in the athletic world for recovery and healing by leading organizations such as The David Leadbetter Golf Academy, NFL Alumni Association (NFLA), and Hospital for Special Surgery’s, Pete Draovitch, PT, MS, ATC, CSCS. Some of the champion athletes using Juvent in their daily training regimens include; Olympic Tennis Champion Mike Bryan, former NFL legend, Ray Lewis, Eric Wood, with the Buffalo Bills and tennis legend Mats Wilander.

Juvent is a Corporate Advisory Roundtable Member of the National Osteoporosis Foundation (NOF).

About Juvent:

Juvent is a part of Regenerative Technologies Corporation, a privately held, Florida based company who manufactures the Juvent Micro-Impact Platform® here in the U.S. The platform provides non-invasive, micro-impact pulses to support bone health, lymphatic drainage, relieve joint and back pain, and enhance balance. The Class I medical exercise and rehabilitation device is the result of more than 20 years and $45 million in R&D, with many peer-reviewed journals articles and 6 human clinical studies (completed or current) with backing from the National Institutes of Health (NIH), NASA, and the U.S. Army. Used by world-renowned medical doctors, trainers, physical therapists, and chiropractors, for more information, visit www.juvent.com or follow us on Twitter @JuventHealth, Facebook Juvent Health and, Facebook Juvent Sports

In the U.S., the Juvent 1000N device is considered investigational for the treatment of osteoporosis or improvement/maintenance of bone mineral density (BMD).

Image Available: http://www.marketwire.com/library/MwGo/2017/6/6/11G140561/Images/Scott_D._Boden,_MD_2017-629ecab0215885c7bb1a88ab05d2c83d.jpg

CONTACT INFORMATION